U.S. Asthma Therapeutics Market (2025 - 2033) Size, Share & Trends Analysis Report By Drug Class (Anti-inflammatory, Bronchodilators), By Device Type (Inhalers, Nebulizers), By Route of Administration (Oral, Inhaled), By Product, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Research Methodology
                    1.3. Information Procurement
                        1.3.1. Purchased Database
                        1.3.2. GVR’s Internal Database
                        1.3.3. Secondary Sources
                        1.3.4. Primary Research
                    1.4. Information/Data Analysis
                    1.5. Market Formulation & Visualization
                    1.6. Data Validation & Publishing
                    1.7. Model Details
                        1.7.1. Commodity flow analysis
                        1.7.2. Regional Market: CAGR Calculation
                    1.8. List of Secondary Sources
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Asthma Therapeutics Market Variable Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market
                        3.1.2. Ancillary Market
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                        3.2.2. Market Restraint Analysis
                        3.2.3. Market Opportunity Analysis
                        3.2.4. Market Challenge Analysis
                    3.3. U.S. Asthma Therapeutics Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Bargaining power of suppliers
                            3.3.1.2. Bargaining power of buyers
                            3.3.1.3. Threat of substitution
                            3.3.1.4. Threat of new entrants
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political & Legal landscape
                            3.3.2.2. Economic and Social landscape
                            3.3.2.3. Technological landscape
                            3.3.2.4. Environmental landscape
                        3.3.3. Regulatory Framework
Chapter 4. U.S. Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Asthma Therapeutics Market: Drug Class Movement Analysis
                    4.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
                    4.4. Anti-inflammatory
                        4.4.1. Anti-inflammatory Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    4.5. Bronchodilators
                        4.5.1. Bronchodilators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    4.6. Combine Therapy
                        4.6.1. Combine Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 5. U.S. Asthma Therapeutics Market: Device Type Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. Asthma Therapeutics Market: Device Type Movement Analysis
                    5.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Device Type, 2021 to 2033 (USD Billion)
                    5.4. Inhalers
                        5.4.1. Inhalers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    5.5. Nebulizers
                        5.5.1. Nebulizers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 6. U.S. Asthma Therapeutics Market: Product Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. Asthma Therapeutics Market by Product
                    6.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
                    6.4. Dry Powder
                        6.4.1. Dry Powder Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    6.5. Metered Dose
                        6.5.1. Metered Dose Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    6.6. Soft Mist
                        6.6.1. Soft Mist Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 7. U.S. Asthma Therapeutics Market: Route of Administration Estimates & Trend Analysis
                    7.1. Segment Dashboard
                    7.2. U.S. Asthma Therapeutics Market: By Route of Administration Movement Analysis
                    7.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
                        7.3.1. Oral
                            7.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        7.3.2. Inhaled
                            7.3.2.1. Inhaled Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        7.3.3. intravenous
                            7.3.3.1. Intravenous Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 8. Competitive Landscape
                    8.1. Market Participant Categorization
                    8.2. Company Market Position Analysis/ Heap Map Analysis
                    8.3. Company Profiles
                        8.3.1. Teva Pharmaceuticals Industries Ltd.
                            8.3.1.1. Participant’s Overview
                            8.3.1.2. Financial Performance
                            8.3.1.3. Application Benchmarking
                            8.3.1.4. Strategic Initiatives
                        8.3.2. GSK plc
                            8.3.2.1. Participant’s Overview
                            8.3.2.2. Financial Performance
                            8.3.2.3. Application Benchmarking
                            8.3.2.4. Strategic Initiatives
                        8.3.3. Merck & Co. Inc.
                            8.3.3.1. Participant’s Overview
                            8.3.3.2. Financial Performance
                            8.3.3.3. Product Benchmarking
                            8.3.3.4. Strategic Initiatives
                        8.3.4. F. Hoffmann-La Roche Ltd
                            8.3.4.1. Participant’s Overview
                            8.3.4.2. Financial Performance
                            8.3.4.3. Product Benchmarking
                            8.3.4.4. Strategic Initiatives
                        8.3.5. AstraZeneca
                            8.3.5.1. Participant’s Overview
                            8.3.5.2. Financial Performance
                            8.3.5.3. Product Benchmarking
                            8.3.5.4. Strategic Initiatives
                        8.3.6. Boehringer Ingelheim International GmbH
                            8.3.6.1. Participant’s Overview
                            8.3.6.2. Financial Performance
                            8.3.6.3. Product Benchmarking
                            8.3.6.4. Strategic Initiatives
                        8.3.7. Sanofi
                            8.3.7.1. Participant’s Overview
                            8.3.7.2. Financial Performance
                            8.3.7.3. Product Benchmarking
                            8.3.7.4. Strategic Initiatives
                        8.3.8. Koninklijke Philips N.V.
                            8.3.8.1. Participant’s Overview
                            8.3.8.2. Financial Performance
                            8.3.8.3. Product Benchmarking
                            8.3.8.4. Strategic Initiatives
                        8.3.9. Covis Pharma
                            8.3.9.1. Participant’s Overview
                            8.3.9.2. Financial Performance
                            8.3.9.3. Product Benchmarking
                            8.3.9.4. Strategic Initiatives
                        8.3.10. Pfizer
                            8.3.10.1. Participant’s Overview
                            8.3.10.2. Financial Performance
                            8.3.10.3. Product Benchmarking
                            8.3.10.4. Strategic Initiatives
                        8.3.11. Regeneron
                            8.3.11.1. Participant’s Overview
                            8.3.11.2. Financial Performance
                            8.3.11.3. Product Benchmarking
                            8.3.11.4. Strategic Initiatives
                        8.3.12. Amgen
                            8.3.12.1. Participant’s Overview
                            8.3.12.2. Financial Performance
                            8.3.12.3. Product Benchmarking
                            8.3.12.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 U.S. Asthma Therapeutics Market, by Drug Class, 2021 - 2033 (USD Billion)
Table 3 U.S. Asthma Therapeutics Market, by Device Type, 2021 - 2033 (USD Billion)
Table 4 U.S. Asthma Therapeutics Market, by Product, 2021 - 2033 (USD Billion)
Table 5 U.S. Asthma Therapeutics Market, by Route of Administration, 2021 - 2033 (USD Billion)

List of Figures

Fig. 1 Market Segmentation
Fig. 2 Market Research Process
Fig. 3 Information Procurement
Fig. 4 Primary Research Pattern
Fig. 5 Market Research Approaches
Fig. 6 Value Chain-Based Sizing & Forecasting
Fig. 7 QFD Modelling for Market Share Assessment
Fig. 8 Market Formulation & Validation
Fig. 9 U.S. Asthma Therapeutics Market Revenue, 2021-2033 (USD Billion)
Fig. 10 U.S. Asthma Therapeutics Market Snapshot
Fig. 11 U.S. Asthma Therapeutics Market Driver Impact
Fig. 12 U.S. Asthma Therapeutics Market Restraint Impact
Fig. 13 U.S. Asthma Therapeutics Product Key Takeaways (USD Billion)
Fig. 14 U.S. Asthma Therapeutics Market: Product Movement Analysis
Fig. 15 Drug Class Market, 2021 - 2033 (USD Billion)
Fig. 16 Anti-inflammatory Market, 2021 - 2033 (USD Billion)
Fig. 17 Bronchodilators Market, 2021 - 2033 (USD Billion)
Fig. 18 Combination Therapy Market, 2021 - 2033 (USD Billion)
Fig. 19 U.S. Asthma Therapeutics Device Type Key Takeaways (USD Billion)
Fig. 20 U.S. Asthma Therapeutics Market: Device Type Movement Analysis
Fig. 21 Inhalers Market, 2021 - 2033 (USD Billion)
Fig. 22 Nebulizers Market, 2021 - 2033 (USD Billion)
Fig. 23 U.S. Asthma Therapeutics Market: Product Movement Analysis
Fig. 24 Dry Powder Market, 2021 - 2033 (USD Billion)
Fig. 25 Metered Dose Market, 2021 - 2033 (USD Billion)
Fig. 26 Soft Mist Market, 2021 - 2033 (USD Billion)
Fig. 27 U.S. Asthma Therapeutics Market Route of Administration Key Takeaways (USD Billion)
Fig. 28 U.S. Asthma Therapeutics Market: Route of Administration Movement Analysis
Fig. 29 Oral Market, 2021 - 2033 (USD Billion)
Fig. 30 Inhaled Market, 2021 - 2033 (USD Billion)
Fig. 31 Intravenous Market, 2021 - 2033 (USD Billion)